Guggenheim Maintains Neutral Rating for The Oncology Institute: Here's What You Need To Know

Guggenheim has decided to maintain its Neutral rating of The Oncology Institute TOI and lower its price target from $6.00 to $3.00.

Shares of The Oncology Institute are trading up 1.41% over the last 24 hours, at $0.49 per share.

A move to $3.00 would account for a 515.01% increase from the current share price.

About The Oncology Institute

The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financia-[=l counseling, clinical trials, comprehensive lab testing, and end-of-life counseling.The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.